SCHEMBL2833774

SCHEMBL2833774

CCCCC(O)C(C)[N+](=O)[O-]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 2/20 0.41
ALDH1A1 P00352 2/20 0.38
CA1 P00915 2/20 0.36
CA2 P00918 5/20 0.35
FDPS P14324 1/20 0.34
CYP2D6 P10635 2/20 0.34
GMNN O75496 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
THPO P40225 1/20 0.34
MTOR P42345 1/20 0.34
BLM P54132 1/20 0.34
KDM4E B2RXH2 1/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
CETP P11597 1/20 0.34
HTT P42858 1/20 0.34
UBE2N P61088 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8355649 0.94 SPHK1 (0.48) SPHK1ALDH1A1CA1CYP2D6GMNN
SCHEMBL6381582 0.92 SPHK1 (0.52) SPHK1ALDH1A1CA1CA2CYP2D6
SCHEMBL6380473 0.92 SPHK1 (0.52) SPHK1ALDH1A1CA1CA2CYP2D6
SCHEMBL15718783 0.92 SPHK1 (0.52) SPHK1ALDH1A1CA1CA2CYP2D6
SCHEMBL6381596 0.87 LMNA (0.37) SPHK1ALDH1A1CA1FDPSLMNA
SCHEMBL17366581 0.87 LMNA (0.37) SPHK1ALDH1A1CA1FDPSLMNA
SCHEMBL11874858 0.82 ALDH1A1 (0.41) ALDH1A1LMNABLM
SCHEMBL11876607 0.81 SPHK1 (0.41) SPHK1ALDH1A1CA1CA2CYP2D6
SCHEMBL6341155 0.78
SCHEMBL1702828 0.78 LCK (0.38) SPHK1ALDH1A1CA2FDPSCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9988397-B2 ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2018-06-05 US disclosed
US-20170267695-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-09-21 US disclosed
EP-2117300-B1 AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS ANGUS CHEMICAL (US) 2017-04-19 EP disclosed
US-9034929-B2 Aminoalcohol and biocide compositions for aqueous based systems ANGUS CHEMICAL COMPANY (US) 2015-05-19 US disclosed
US-20120311922-A1 CORROSION AND MICROBIAL CONTROL IN HYDROCARBONACEOUS COMPOSITIONS TINETTI SHEILA M (US) 2012-12-13 US disclosed
EP-2244570-A2 IMPROVED CORROSION AND MICROBIAL CONTROL IN HYDROCARBONACEOUS COMPOSITIONS Dow Global Technologies Inc. (US) 2010-11-03 EP disclosed
US-20100242341-A1 CORROSION AND MICROBIAL CONTROL IN HYDROCARBONACEOUS COMPOSITIONS DOW GLOBAL TECHNOLOGIES LLC 2010-09-30 US disclosed
US-20100093736-A1 AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS ANGUS CHEMICAL COMPANY (US) 2010-04-15 US disclosed
EP-2117300-A2 AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS ANGUS CHEMICAL COMPANY (US) 2009-11-18 EP disclosed
WO-2009085552-A2 IMPROVED CORROSION AND MICROBIAL CONTROL IN HYDROCARBONACEOUS COMPOSITIONS DOW GLOBAL TECHNOLOGIES INC. (US) 2009-07-09 WO disclosed
WO-2008088632-A2 AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS ANGUS CHEMICAL COMPANY (US) 2008-07-24 WO disclosed
EP-0976734-B1 Selective inhibitors of viral or bacterial neuraminidase GILEAD SCIENCES INC (US) 2005-09-28 EP disclosed
US-20050176758-A1 2-(hydroxy or methoxymethoxy)-4-(carboxy or alkoxycarbonyl)-5-(fluoro or hydrogen)-7-oxabicyclo(4.1.0)hept-3-ene chemical intermediates to neuraminidase inhibitors GILEAD SCIENCES, INC. 2005-08-11 US disclosed
US-6225341-B1 FOR INHIBITING NEURAMINIDASE; FOR THERAPY AND PROPHYLAXIS OF VIRUS INFECTION GILEAD SCIENCES, INC. 2001-05-01 US disclosed
EP-0759917-B1 NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES GILEAD SCIENCES INC (US) 2000-04-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267695-A1 ERK INHIBITORS MAPK1, MAP3K1, MAPK4 SPHK1 207/4885ALDH1A1 331/4885CA1 3114/4885
US-20100093736-A1 AMINOALCOHOL AND BIOCIDE COMPOSITIONS FOR AQUEOUS BASED SYSTEMS ADH1C, ADH1A, ADH5 SPHK1 3286/4885ALDH1A1 31/4885CA1 1786/4885
US-20050176758-A1 2-(hydroxy or methoxymethoxy)-4-(carboxy or alkoxycarbonyl)-5-(fluoro or hydrogen)-7-oxabicyclo(4.1.0)hept-3-ene chemical intermediates to neuraminidase inhibitors NEU3, NEU1, NEU4 SPHK1 2790/4885ALDH1A1 374/4885CA1 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.